See today's BioWorld Asia
To read the full story, subscribe or sign in.

MEI: FDA waves Tidal away in rough PI3K waters, wants randomized trial

March 29, 2022
By Randy Osborne
The beleaguered PI3K-delta inhibitor space took another blow after MEI Pharma Inc. and partner Kyowa Kirin Co. Ltd. said the U.S. FDA won’t greenlight zandelisib without data from a randomized study.
BioWorld Asia Clinical Regulatory Cancer Japan FDA